Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET
- 30 September 2010
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (13), 2432-2440
- https://doi.org/10.1016/j.ejca.2010.06.121
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2008
- Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized TrialJNCI Journal of the National Cancer Institute, 2008
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing StrategiesThe Oncologist, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinomaCancer Cell, 2002